Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 28-35 , 25 January 2010

Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA/6-MP

  • Alessandra Aldinucci

      Affiliations

    • Department of Neurological Sciences, University of Florence, Italy
    • Corresponding Author InformationCorresponding author. Department of Neurological Sciences, viale Pieraccini 6, 50134 Florence, Italy. Tel./fax: +39 0554271377.
    • ,
  • Tiziana Biagioli

      Affiliations

    • Department of Neurological Sciences, University of Florence, Italy
    • ,
  • Cinzia Manuelli

      Affiliations

    • Department of Dermatological Sciences, University of Florence, Italy
    • ,
  • Anna Maria Repice

      Affiliations

    • Department of Neurological Sciences, University of Florence, Italy
    • ,
  • Luca Massacesi

      Affiliations

    • Department of Neurological Sciences, University of Florence, Italy
    • ,
  • Clara Ballerini

      Affiliations

    • Department of Neurological Sciences, University of Florence, Italy

Received 23 July 2009 ,Revised 15 October 2009 ,Accepted 2 November 2009.

References 

  1. Abdou NI, Zweiman B, Casella SR. Effects of azathioprine therapy on bone marrow-dependent and thymus-dependent cells in man. Clin. Exp. Immunol. 1973;13:55–64
  2. Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 2007;37(3):686–695
  3. Andreone PA, Olivari MT, Elick B, Arentzen CE, Sibley RK, Bolman RM, et al. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J. Heart Transplant. 1986;5(1):13–19
  4. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 2007;8(2):172–180
  5. Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347(8996):215–219
  6. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet. 1988;2(8604):179–183
  7. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost?. J. Neurol. Neurosurg. Psychiatry. 2001;70(5):574–579
  8. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 1990;30(4):358–363
  9. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology. 1985;89(5):1084–1091
  10. De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann. Rheum. Dis. 1981;40(6):560–563
  11. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 2002;16(7):1225–1232
  12. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18(1):27–34
  13. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001;194(6):769–779
  14. Ifergan I, Kébir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, et al. The blood–brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2008;131(Pt 3):785–799
  15. Kuwano Y, Prazma CM, Yazawa N, Watanabe R, Ishiura N, Kumanogoh A, et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int. Immunol. 2007;19(8):977–992
  16. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 2004;202:96–105
  17. Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 2002;23(6):273–275
  18. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 1992;43:329–335
  19. Liu W, Ouyang X, Yang J, Liu J, Li Q, Gu Y, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 2009;284(36):24006–24016
  20. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J. Clin. Invest. 2003;111(8):1133–1145
  21. Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch. Neurol. 2005;62(12):1843–1847
  22. McGeown MG, Douglas JF, Donaldson RA, Hill CM, Kennedy JA, Loughridge WG, et al. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet. 1988;1(8592):983–985
  23. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005;11(3):335–339
  24. Miller SD, McMahon EJ, Schreiner B, Bailey SL. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 2007;1103:179–191
  25. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin–radixin–moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 2006;176(1):640–651
  26. Prazma CM, Tedder TF. Dendritic cell CD83: a therapeutic target or innocent bystander?. Immunol. Lett. 2008;115(1):1–8
  27. Riol-Blanco L, Sánchez-Sánchez N, Torres A, Tejedor A, Narumiya S, Corbí AL, et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J. Immunol. 2005;174(7):4070–4080
  28. Röllinghoff M, Schrader J, Wagner H. Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin. Exp. Immunol. 1973;15:261–269
  29. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995;182(2):389–400
  30. Sánchez-Sánchez N, Riol-Blanco L, Rodríguez-Fernández JL. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 2006;176(9):5153–5159
  31. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Capello E, Mancardi GL, et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 2006;65(2):124–141
  32. Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain. 2006;129(Pt 5):1293–1305
  33. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 2003;111(8):1133–1145
  34. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 2006;176(12):7768–7774(Erratum in: J Immunol. 2006 177(3), 2025)
  35. Vergelli M, Hemmer B, Utz U, Vogt A, Kalbus M, Tranquill L, et al. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99). Eur. J. Immunol. 1996;26(11):2624–2634
  36. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991;338(8774):1051–1055
  37. Zhou LJ, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 1992;149(2):735–742

PII: S0165-5728(09)00435-4

doi: 10.1016/j.jneuroim.2009.11.001

Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 28-35 , 25 January 2010

Article Tools

* Image Usage & Resolution